CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs

Patent ExpiryKeytrudaOpdivoEliquisPositive
AI Analysis

Summary

BMO Capital Markets analyst favors Merck's strategy to address Keytruda patent cliff losses over Bristol Myers Squibb's plans to replace revenue from Opdivo and Eliquis exclusivity losses.

Importance:3/10
Sentiment:
0.60
patent_cliffrevenue_replacementcompetitive_analysisanalyst_note
Related Companies

Read the original article

Published by BioSpace on October 2, 2026 2:58 PM

Read Original